Press coverage about ResMed (NYSE:RMD) has been trending somewhat positive on Friday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ResMed earned a news impact score of 0.14 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.7105204572294 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

ResMed (NYSE RMD) opened at 72.62 on Friday. The stock has a market cap of $10.33 billion, a PE ratio of 30.26 and a beta of 0.83. ResMed has a 1-year low of $56.59 and a 1-year high of $79.63. The stock has a 50 day moving average price of $76.66 and a 200-day moving average price of $72.21.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.02. The firm had revenue of $556.69 million during the quarter, compared to analyst estimates of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. ResMed’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.74 earnings per share. On average, equities analysts expect that ResMed will post $3.03 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 21st. Investors of record on Thursday, August 17th will be issued a $0.35 dividend. This is a positive change from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.93%. ResMed’s payout ratio is presently 54.77%.

Several equities research analysts have weighed in on RMD shares. BidaskClub upgraded ResMed from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Citigroup Inc cut ResMed from a “buy” rating to a “neutral” rating in a report on Friday, April 28th. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a report on Wednesday, August 2nd. Finally, Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $65.63.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at

In related news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $71.02, for a total value of $88,775.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Sulpizio sold 65,887 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $77.82, for a total value of $5,127,326.34. Following the completion of the sale, the director now owns 4,429 shares of the company’s stock, valued at approximately $344,664.78. The disclosure for this sale can be found here. Insiders sold 180,260 shares of company stock valued at $13,715,644 in the last quarter. 1.97% of the stock is owned by company insiders.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with's FREE daily email newsletter.